Kris Elverum

Kris Elverum currently serves as the President and Chief Executive Officer of AIRNA, a company focused on RNA editing therapeutics, and is a member of the Board of Advisors for Navega Therapeutics. Previous experience includes roles as a consultant for biopharma companies, CEO of 4:59 NewCo, and Senior Vice President of Business Development and Strategy at Rubius Therapeutics, where major strategic initiatives were implemented. Further experience includes serving as Senior Vice President of Corporate Development at Turnstone Biologics, Chief Business Officer at SQZ Biotech, and various leadership roles at Novartis. Kris Elverum began a career at McKinsey & Company and holds an M.B.A. and a B.S. in Business with a minor in Chemistry from the University of Minnesota - Carlson School of Management.